LB1909 / Legend Biotech - LARVOL DELTA

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=1; Terminated; Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University; N=28 ➔ 1; Trial completion date: May 2023 ➔ May 2021; Recruiting ➔ Terminated; Suitable patients were not recruited

Clinical • Enrollment change • Trial completion date • Trial termination • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=28; Recruiting; Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University; Trial primary completion date: May 2023 ➔ May 2021

Clinical • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University; N=30 ➔ 0; Recruiting ➔ Withdrawn

CAR T-Cell Therapy • Clinical • Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukaemia • Hematological Malignancies • Leukemia • Oncology • CD19